Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: Efficacy, safety, and patient acceptability

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 483-490

  Barkin, Jack ^a,b  

^a HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

5 alpha reductase inhibitors; Alpha blockers; Benign prostatic hyperplasia; Benign Prostatic hyperplasia impact index; BII; Combination therapy; Lower urinary tract symptoms; Patient's perception of study medication; Quality of life

Indexed keywords

DOXAZOSIN; DUTASTERIDE; DUTASTERIDE PLUS TAMSULOSIN; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

ARTICLE; BREAST TENDERNESS; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DISEASE COURSE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GYNECOMASTIA; HISTORY OF MEDICINE; HUMAN; LIBIDO DISORDER; MASTALGIA; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROGRADE EJACULATION; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SIDE EFFECT; SPERM; TOTAL QUALITY MANAGEMENT; WELLBEING;

EID: 84859146808     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S14032     Document Type: Article

References (25)

1. Barry MJ, Fowler FL, O'Leary MP, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549-1557.
2. Barry MJ, Williford WO, Chang W, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol. 1995;154(5):1770-1774.
3. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol. 2001;39(4):390-399.
4. Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G. The long-term outcome of medical therapy for BPH. Eur Urol. 2007;51(6):1522-1533.
5. Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. J Urol. 2006;176(4 Pt 1):1299-1306.
6. Djavan B, Waldert M, Ghawidel C, Marberger M. Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol. 2004;14(1):45-50.
7. Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int. 2006;97(Suppl 2):7-11; discussion 21-22.
8. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398.
9. Oelke M, Bachmann A, Descazeaud M, et al. EAU Guidelines on Conservative Treatment of Non-neurogenic Male LUTS. Arnhem, The Netherlands: European Association of Urology; 2010. Available from: http://www.uroweb.org/gls/pdf/BPH%202010.pdf. Accessed June 24, 2011.
10. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179-2184.
11. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119-126.
12. Lepor H, Williford WO, Barry MJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(8):533-539.
13. Lepor H. Nonoperative management of benign prostatic hyperplasia. J Urol. 1989;141:1283-1289.
14. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557-563.
15. Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006;175(1):217-22; discussion 220-221.
16. Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46(4):488-495.
17. Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol. 1995;76(3):325-336.
18. Roehrborn C, Boyle P, Gould AL, Waldstreicher J. Serum prostatespecific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581-589.
19. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-131.
20. Siami P, Roehrborn CG, Barkin J, et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials. 2007;28(6):770-779.
21. Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostaterelated surgery. Curr Med Res Opin. 2009;25(11):2663-2669.
22. Roehrborn C, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2009;179(2):616-621; discussion 621.
23. Barkin J, Roehrborn C, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int. 2008;103(7):919-926.
24. Montorsi F, Henkel T, Geboers A, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract. 2010;64(8):1042-1051.
25. Barkin J, Guimarães M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 2003;44(4):461-466.